2025
95 Assessing genetic diversity of the Pfs25 vaccine candidate: Implications for malaria transmission-blocking vaccine in Africa
Orfano A, Cisse A, Sheng Z, Guo Y, Han L, Thiam L, Mangou K, Moore A, Ba A, Li R, Pouye M, Diallo F, Sene S, Ngom E, Sadio B, Mbengue A, Membi C, Bazié T, Somé F, Olson N, Patel S, Shapiro L, Parikh S, Foy B, Cappello M, Premji Z, Dabiré R, Ouedraogo J, Bei A. 95 Assessing genetic diversity of the Pfs25 vaccine candidate: Implications for malaria transmission-blocking vaccine in Africa. Journal Of Clinical And Translational Science 2025, 9: 29-29. PMCID: PMC12050472, DOI: 10.1017/cts.2024.767.Peer-Reviewed Original ResearchSingle nucleotide polymorphismsTransmission-blocking vaccinesGenetic diversityComplex infectionSymptomatic P. falciparum infectionsMalaria transmission-blocking vaccineVaccine candidatesVariant frequenciesNovel single nucleotide polymorphismsNonsynonymous single nucleotide polymorphismsRare variantsFrequency of single nucleotide polymorphismsP. falciparum 3D7Plasmodium falciparum samplesAmplicon deep sequencingMalaria eliminationCountry-specific prevalenceEndemic African countriesPfs25 proteinGeneious softwareParasite genetic diversityProportion of mutant allelesAmplicon sequencingPfs25Mutant allelesAltering the intracellular trafficking of Necator americanus GST-1 antigen yields novel hookworm mRNA vaccine candidates
De Oliveira A, Versteeg L, Briggs N, Adhikari R, Villar M, Redd J, Hotez P, Bottazzi M, Pollet J. Altering the intracellular trafficking of Necator americanus GST-1 antigen yields novel hookworm mRNA vaccine candidates. PLOS Neglected Tropical Diseases 2025, 19: e0012809. PMID: 39792959, PMCID: PMC11756802, DOI: 10.1371/journal.pntd.0012809.Peer-Reviewed Original ResearchConceptsAntigen-specific antibodiesMRNA vaccine candidateMRNA vaccinesVaccine candidatesNa-GST-1Plasma membrane-anchoredRobust CD8+ T-cell responsesCD8+ T cell responsesMemory T cell populationsTiters of antigen-specific antibodiesLevels of antigen-specific antibodiesT cell responsesT cell populationsRecombinant Na-GST-1In vivo efficacySubunit vaccine candidateInduce humoral responsesImmunogenicity findingsNeutralizing antibodiesClinical studiesDevelopment of multivalent vaccinesHumoral responseRNA vaccinesImmune responsePeptide presentation
2024
Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45
Bansal G, da Silva Araujo M, Cao Y, Shaffer E, Araujo J, Medeiros J, Hayashi C, Vinetz J, Kumar N. Transmission-reducing and -enhancing monoclonal antibodies against Plasmodium vivax gamete surface protein Pvs48/45. Infection And Immunity 2024, 92: e00374-23. PMID: 38289124, PMCID: PMC10929423, DOI: 10.1128/iai.00374-23.Peer-Reviewed Original ResearchDirect membrane feeding assaysTransmission-blocking vaccinesTransmission-blocking vaccine developmentMalaria transmission-blocking vaccineBlocked oocyst developmentInfectivity of gametocytesMale gamete fertilityMonoclonal antibodiesMembrane feeding assaysTransmission-blocking activityPvs48/45Activity of antibodiesNon-overlapping epitopesOocyst developmentPotential vaccine candidatesIndividual MAbsVaccine candidatesEffective immunogensChallenge modelMAbAntibodiesGametocytesEpitopesRecombinant fragmentsEnhanced activity
2023
Bacterial production of recombinant contraceptive vaccine antigen from CatSper displayed on a human papilloma virus-like particle
Nand K, Jordan T, Yuan X, Basore D, Zagorevski D, Clarke C, Werner G, Hwang J, Wang H, Chung J, McKenna A, Jarvis M, Singh G, Bystroff C. Bacterial production of recombinant contraceptive vaccine antigen from CatSper displayed on a human papilloma virus-like particle. Vaccine 2023, 41: 6791-6801. PMID: 37833124, DOI: 10.1016/j.vaccine.2023.09.044.Peer-Reviewed Original ResearchConceptsVirus-like particlesSperm hyperactivated motilityHuman papilloma virusInclusion bodiesLong-acting protectionCalcium ion channelsNon-hormonal interventionsContraceptive efficacyHyperactivated motilityPapilloma virusPrincipal pieceSperm tailContraceptive vaccineBALB/c miceHypervariable regionCatSperVaccine antigensBacterial productionVaccine candidatesIon channelsIn vitroVaccinePregnancyRecombinant vaccineExtracellular loopVaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models
Lorenzo M, Marín-López A, Chiem K, Jimenez-Cabello L, Ullah I, Utrilla-Trigo S, Calvo-Pinilla E, Lorenzo G, Moreno S, Ye C, Park J, Matía A, Brun A, Sánchez-Puig J, Nogales A, Mothes W, Uchil P, Kumar P, Ortego J, Fikrig E, Martinez-Sobrido L, Blasco R. Vaccinia Virus Strain MVA Expressing a Prefusion-Stabilized SARS-CoV-2 Spike Glycoprotein Induces Robust Protection and Prevents Brain Infection in Mouse and Hamster Models. Vaccines 2023, 11: 1006. PMID: 37243110, PMCID: PMC10220993, DOI: 10.3390/vaccines11051006.Peer-Reviewed Original ResearchVaccine candidatesStrong T cell responsesAngiotensin-converting enzyme 2Prime-boost regimensT cell responsesFull-length SARS-CoV-2 spike proteinEffective COVID-19 vaccineGolden Syrian hamstersSARS-CoV-2 spike glycoproteinSARS-CoV-2 spike proteinCOVID-19 vaccineRecombinant MVA vaccinesSARS-CoV-2S proteinBrain infectionMVA vaccinesCell-cell fusionAmino acid substitutionsVaccine platformHamster modelEnzyme 2Recombinant MVAVaccine vectorAnimal modelsRobust immunityA ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates
Weidenbacher P, Sanyal M, Friedland N, Tang S, Arunachalam P, Hu M, Kumru O, Morris M, Fontenot J, Shirreff L, Do J, Cheng Y, Vasudevan G, Feinberg M, Villinger F, Hanson C, Joshi S, Volkin D, Pulendran B, Kim P. A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Nature Communications 2023, 14: 2149. PMID: 37069151, PMCID: PMC10110616, DOI: 10.1038/s41467-023-37417-9.Peer-Reviewed Original ResearchConceptsNeutralizing antiseraLonger-lasting immunityNon-human primatesFerritin-basedOnce-yearlyNanoparticle vaccineSARS-CoV-2 variantsOmicron BQVaccine dosePediatric useAnamnestic responseInitial immunizationVaccine candidatesSARS-CoV-2Development of COVID-19 vaccinesCell linesCOVID-19 vaccineVaccineSARS-CoV-1Cell culturesImmunityStructure-guided stabilization improves the ability of the HIV-1 gp41 hydrophobic pocket to elicit neutralizing antibodies
Bruun T, Tang S, Erwin G, Deis L, Fernandez D, Kim P. Structure-guided stabilization improves the ability of the HIV-1 gp41 hydrophobic pocket to elicit neutralizing antibodies. Journal Of Biological Chemistry 2023, 299: 103062. PMID: 36841484, PMCID: PMC10064241, DOI: 10.1016/j.jbc.2023.103062.Peer-Reviewed Original Research
2022
Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5
Mangou K, Moore A, Thiam L, Ba A, Orfanó A, Desamours I, Ndegwa D, Goodwin J, Guo Y, Sheng Z, Patel S, Diallo F, Sene S, Pouye M, Faye A, Thiam A, Nunez V, Diagne C, Sadio B, Shapiro L, Faye O, Mbengue A, Bei A. Structure-guided insights into potential function of novel genetic variants in the malaria vaccine candidate PfRh5. Scientific Reports 2022, 12: 19403. PMID: 36371450, PMCID: PMC9653458, DOI: 10.1038/s41598-022-23929-9.Peer-Reviewed Original ResearchConceptsImmune evasionSingle nucleotide polymorphismsPopulation prevalenceVaccine-induced protective immunityP. falciparum positive samplesFalciparum positive samplesPlasmodium falciparum antigensMalaria vaccine candidateNovel single nucleotide polymorphismsInhibitory monoclonal antibodiesProtective immunityFalciparum antigensMalaria deathsEffective vaccineEfficacious vaccineVaccine candidatesPfRH5Infected individualsVaccine targetsMonoclonal antibodiesLow overall frequencyReceptor bindingNovel genetic variantsVaccineOverall frequencyIdentification of novel conserved Ixodes vaccine candidates; a promising role for non-secreted salivary gland proteins
Trentelman J, de Vogel F, Colstrup E, Sima R, Coumou J, Koetsveld J, Klouwens M, Nayak A, Ersoz J, Barriales D, Tomás-Cortázar J, Narasimhan S, Hajdusek O, Anguita J, Hovius J. Identification of novel conserved Ixodes vaccine candidates; a promising role for non-secreted salivary gland proteins. Vaccine 2022, 40: 7593-7603. PMID: 36357287, DOI: 10.1016/j.vaccine.2022.10.032.Peer-Reviewed Original ResearchConceptsTick salivary gland proteinsAnti-tick vaccinesTick immunityVaccine candidatesSalivary gland proteinsLyme borreliosisNymphal I. ricinusExperimental Lyme borreliosisImmune animalsVaccination studiesTick feedingI. ricinusTick attachmentNymphal ticksPathogen transmissionGuinea pigsIxodes scapularisI. scapularisGland proteinsVaccineCausative agentImmunityMain vectorIdentification of novelPromising roleSimplified Purification of Glycoprotein-Modified Ferritin Nanoparticles for Vaccine Development
Weidenbacher P, Musunuri S, Powell A, Tang S, Do J, Sanyal M, Kim P. Simplified Purification of Glycoprotein-Modified Ferritin Nanoparticles for Vaccine Development. Biochemistry 2022, 62: 292-299. PMID: 35960597, PMCID: PMC9850919, DOI: 10.1021/acs.biochem.2c00241.Peer-Reviewed Original ResearchMultiplexed LNP-mRNA vaccination against pathogenic coronavirus species
Peng L, Fang Z, Renauer PA, McNamara A, Park JJ, Lin Q, Zhou X, Dong MB, Zhu B, Zhao H, Wilen CB, Chen S. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Reports 2022, 40: 111160. PMID: 35921835, PMCID: PMC9294034, DOI: 10.1016/j.celrep.2022.111160.Peer-Reviewed Original ResearchConceptsAntibody responseCoronavirus speciesSequential vaccinationSARS-CoVAntigen-specific antibody responsesSARS-CoV-2 DeltaAdaptive immune cellsEffective immune responsePotent antibody responsesCOVID-19 vaccineSARS-CoV-2MRNA vaccine candidatesActivated B cellsSingle-cell RNA sequencing profilesRNA sequencing profilesSimultaneous vaccinationAntibody immunityVaccination scheduleImmune profileImmune cellsImmune responseVaccine candidatesMERS-CoV.Animal modelsB cellsOmicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2
Fang Z, Peng L, Filler R, Suzuki K, McNamara A, Lin Q, Renauer PA, Yang L, Menasche B, Sanchez A, Ren P, Xiong Q, Strine M, Clark P, Lin C, Ko AI, Grubaugh ND, Wilen CB, Chen S. Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nature Communications 2022, 13: 3250. PMID: 35668119, PMCID: PMC9169595, DOI: 10.1038/s41467-022-30878-4.Peer-Reviewed Original ResearchConceptsHeterologous boosterSARS-CoV-2Antibody responseMRNA vaccinesMRNA vaccinationDelta variantOmicron variantType of vaccinationStrong antibody responseMRNA vaccine candidatesVaccine candidatesNeutralization potencyImmune evasionSARS-CoV.Two weeksComparable titersVaccinationVaccineTiters 10MiceOmicronWeeksWA-1LNP-mRNABoosterCombining Cellular Immunology With RNAseq to Identify Novel Chlamydia T-Cell Subset Signatures
Johnson RM, Asashima H, Mohanty S, Shaw AC. Combining Cellular Immunology With RNAseq to Identify Novel Chlamydia T-Cell Subset Signatures. The Journal Of Infectious Diseases 2022, 225: 2033-2042. PMID: 35172331, PMCID: PMC9159333, DOI: 10.1093/infdis/jiac051.Peer-Reviewed Original ResearchConceptsProtective T cell clonesAntibacterial effector mechanismsT cells residentB cell helpT cell clonesCytokine polarizationImmune miceIL-10Protective immunityVaccine trialsIL-13Surrogate biomarkerEffector mechanismsGenital tractT cellsVaccine candidatesChlamydia trachomatisCells residentHelper functionCellular immunologyMouse studiesHuman investigationsReproductive tractGranzyme A.Investigational data
2021
Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States
Hook SA, Hansen AP, Niesobecki SA, Meek JI, Bjork JKH, Kough EM, Peterson MS, Schiffman EK, Rutz HJ, Rowe AJ, White JL, Peel JL, Biggerstaff BJ, Hinckley AF. Evaluating public acceptability of a potential Lyme disease vaccine using a population-based, cross-sectional survey in high incidence areas of the United States. Vaccine 2021, 40: 298-305. PMID: 34895785, PMCID: PMC11705932, DOI: 10.1016/j.vaccine.2021.11.065.Peer-Reviewed Original ResearchConceptsLyme disease vaccineDisease vaccineSurvey-weighted descriptive statisticsMultivariable multinomial logistic regression modelsCross-sectional studyLyme disease incidenceHigh incidence areaCross-sectional surveyLogistic regression modelsSafety concernsMultinomial logistic regression modelsVaccine uptakeAdults 45Vaccine parametersVaccine candidatesVaccine attitudesPrevention optionsHealthcare providersWeb-based surveyVaccineSociodemographic characteristicsIncidence areaLyme diseaseDisease incidenceIncidenceEffect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens
Amoani B, Gyan B, Sakyi SA, Abu EK, Nuvor SV, Barnes P, Sarkodie-Addo T, Ahenkorah B, Sewor C, Dwomoh D, Theisen M, Cappello M, Wilson MD, Adu B. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens. BMC Infectious Diseases 2021, 21: 332. PMID: 33832450, PMCID: PMC8028774, DOI: 10.1186/s12879-021-06027-5.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAged, 80 and overAlbendazoleAnthelminticsAntibodies, ProtozoanAntigens, ProtozoanCase-Control StudiesChildChild, PreschoolCross-Sectional StudiesFemaleHookworm InfectionsHumansImmunoglobulin GLongitudinal StudiesMalaria VaccinesMalaria, FalciparumMaleMiddle AgedParasitemiaProtozoan ProteinsYoung AdultConceptsMerozoite surface protein 3Antibody responseHookworm infectionMalaria vaccine candidateConstituent antigensP. falciparumGLURP-R0IgG3 levelsVaccine candidatesLongitudinal cross-sectional studyHigher IgG3 levelsUninfected endemic controlsP. falciparum infectionPlasmodium falciparum merozoite surface protein 3Levels of IgG1Kato-Katz methodCross-sectional studyHigher antibody responseMalaria vaccine efficacyKintampo North MunicipalityAnthelmintic treatmentHookworm treatmentMalaria parasitaemiaAlbendazole treatmentEndemic controlsA live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus
Wunder EA, Adhikarla H, Hamond C, Bonner K, Liang L, Rodrigues CB, Bisht V, Nally JE, Alt DP, Reis MG, Diggle PJ, Felgner PL, Ko A. A live attenuated-vaccine model confers cross-protective immunity against different species of the Leptospira genus. ELife 2021, 10: e64166. PMID: 33496263, PMCID: PMC7837694, DOI: 10.7554/elife.64166.Peer-Reviewed Original ResearchConceptsCross-protective immunityPathogenic Leptospira speciesTerms of morbidityLeptospira speciesTransient bacteremiaSingle doseAntibody responseImmune responseApplicable vaccinesVaccine candidatesAnimal modelsEffective preventionAttenuated mutantsZoonotic diseaseLeptospira genusPotential correlatesDisease transmissionDiseaseLeptospirosisImmunityBacteremiaMorbidityImmunizationVaccineRelevant proteinsA Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV‑2 in Mice
Powell A, Zhang K, Sanyal M, Tang S, Weidenbacher P, Li S, Pham T, Pak J, Chiu W, Kim P. A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV‑2 in Mice. ACS Central Science 2021, 7: 183-199. PMID: 33527087, PMCID: PMC7805605, DOI: 10.1021/acscentsci.0c01405.Peer-Reviewed Original ResearchSARS-CoV-2 spikeSelf-assembling ferritin nanoparticlesElicitation of neutralizing antibodiesFerritin-based vaccinesReceptor-binding domainSARS-CoV-2 vaccinesSingle-dose vaccinationImmunization of miceSubunit vaccine candidateVaccine elicitationCOVID-19 patientsEffective SARS-CoV-2 vaccineNeutralization titersClinical trialsConvalescent plasmaPublic health prioritySpike receptor-binding domainAntibody responseNanoparticle platformPseudovirus assayVaccine candidatesMonoclonal antibodiesSARS-CoV-2Ferritin nanoparticlesMice
2020
Assessing COVID-19 vaccine literacy: a preliminary online survey
Biasio L, Bonaccorsi G, Lorini C, Pecorelli S. Assessing COVID-19 vaccine literacy: a preliminary online survey. Human Vaccines & Immunotherapeutics 2020, 17: 1304-1312. PMID: 33118868, PMCID: PMC8078752, DOI: 10.1080/21645515.2020.1829315.Peer-Reviewed Original ResearchConceptsCOVID-19 vaccine literacyCOVID-19 vaccine candidatesFuture COVID-19 vaccineValue of immunizationMean functional scoreHealth literacy skillsCOVID-19 vaccineRapid online surveyFunctional scoresVL levelsCurrent vaccinationInfectious disease outbreaksSelf-report toolVaccine literacyGeneral populationHealth literacyVaccine candidatesVaccinationScientific evidenceOnline surveyDisease outbreaksScoresCOVID-19 InfodemicPreliminary online surveyImmunizationRepeat tick exposure elicits distinct immune responses in guinea pigs and mice
Kurokawa C, Narasimhan S, Vidyarthi A, Booth CJ, Mehta S, Meister L, Diktas H, Strank N, Lynn GE, DePonte K, Craft J, Fikrig E. Repeat tick exposure elicits distinct immune responses in guinea pigs and mice. Ticks And Tick-borne Diseases 2020, 11: 101529. PMID: 32993942, PMCID: PMC7530331, DOI: 10.1016/j.ttbdis.2020.101529.Peer-Reviewed Original ResearchConceptsGuinea pigsElicit distinct immune responsesDistinct immune responsesGuinea pig modelLocal blood flowImmune animalsInflammatory pathwaysTick rejectionMechanisms of resistanceImmune responseMouse modelVaccine candidatesBite siteBlood flowPig modelCoagulation pathwayComplement activationAcquired ResistanceProtective antigenTick detachmentTick proteinsBlood mealMiceTick infestationRNA sequencingThe VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19
McAteer J, Yildirim I, Chahroudi A. The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19. Clinical Infectious Diseases 2020, 71: 703-705. PMID: 32282038, PMCID: PMC7184475, DOI: 10.1093/cid/ciaa433.Peer-Reviewed Original ResearchConceptsSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Respiratory syndrome coronavirus 2Syndrome coronavirus 2Vaccines actCoronavirus 2Clinical trialsVaccine hesitancyVaccine candidatesNovel vaccinesCOVID-19COVID-19 pandemicVaccineTimes of COVID19PandemicTrials
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply